Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, KalVista Pharmaceuticals (KALV) has a market cap of $0.60 billion USD. According to our data, KalVista Pharmaceuticals is ranked No.5741 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $0.60 B |
42.77%
|
| Dec 31, 2024 | $0.42 B |
-30.86%
|
| Dec 29, 2023 | $0.61 B |
81.21%
|
| Dec 30, 2022 | $0.33 B |
-48.90%
|
| Dec 31, 2021 | $0.65 B |
-30.33%
|
| Dec 31, 2020 | $0.94 B |
6.63%
|
| Dec 31, 2019 | $0.88 B |
-9.82%
|
| Dec 31, 2018 | $0.98 B |
102.56%
|
| Dec 29, 2017 | $0.48 B |
37.91%
|
| Dec 30, 2016 | $0.35 B |
-86.05%
|
| Dec 31, 2015 | $2.50 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 BioCryst Pharmaceuticals
BCRX
|
$1.55 B |
-0.000 M
|
USA
|
 Ionis Pharmaceuticals
IONS
|
$4.51 B |
0.000 M
|
USA
|
 Alnylam Pharmaceuticals
ALNY
|
$29.89 B |
-0.001 M
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$128.67 B |
-0.003 M
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 Sarepta Therapeutics
SRPT
|
$5.28 B |
-0.000 M
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Moderna
MRNA
|
$10.14 B |
-0.001 M
|
USA
|
 BioMarin Pharmaceutical
BMRN
|
$11.51 B |
-0.000 M
|
USA
|
 Intellia Therapeutics
NTLA
|
$0.76 B |
-0.000 M
|
USA
|
 CRISPR Therapeutics
CRSP
|
$3.34 B |
0.000 M
|
Switzerland
|
 Editas Medicine
EDIT
|
$0.11 B |
0.000 M
|
USA
|
 Sangamo Therapeutics
SGMO
|
$0.17 B |
0.000 M
|
USA
|
| Market Cap | = | KALV Stock Price | * | KALV Shares Outstanding |
| = | $12.02 | * | 49.72 M | |
| = | $0.60 B |